Zacks Research Issues Optimistic Outlook for BHC Earnings

Bausch Health Companies Inc. (NYSE:BHC - Free Report) - Stock analysts at Zacks Research lifted their Q3 2025 earnings per share (EPS) estimates for shares of Bausch Health Companies in a research note issued to investors on Tuesday, December 17th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.15 for the quarter, up from their prior estimate of $1.12. The consensus estimate for Bausch Health Companies' current full-year earnings is $3.74 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2025 earnings at $1.25 EPS.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The business had revenue of $2.51 billion for the quarter, compared to analysts' expectations of $2.42 billion. During the same quarter last year, the business earned $1.03 earnings per share. The firm's quarterly revenue was up 12.2% compared to the same quarter last year.

Other research analysts have also recently issued research reports about the stock. Royal Bank of Canada upped their price target on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a "sector perform" rating in a report on Friday, November 1st. StockNews.com upgraded Bausch Health Companies from a "hold" rating to a "buy" rating in a report on Friday, October 25th. Finally, Evercore ISI raised Bausch Health Companies to a "hold" rating in a research note on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $7.75.

Bausch Health Companies Stock Up 1.1 %

Shares of BHC traded up $0.08 on Friday, hitting $7.47. The company's stock had a trading volume of 1,232,922 shares, compared to its average volume of 2,748,763. The firm's fifty day moving average price is $8.34 and its 200-day moving average price is $7.27. Bausch Health Companies has a fifty-two week low of $3.96 and a fifty-two week high of $11.46. The firm has a market capitalization of $2.70 billion, a price-to-earnings ratio of -15.56 and a beta of 0.69.

Institutional Investors Weigh In On Bausch Health Companies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldentree Asset Management LP increased its position in shares of Bausch Health Companies by 31.0% in the third quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company's stock valued at $239,552,000 after acquiring an additional 6,958,717 shares during the last quarter. Bank of Montreal Can grew its stake in Bausch Health Companies by 234.0% in the third quarter. Bank of Montreal Can now owns 3,833,179 shares of the company's stock valued at $31,598,000 after purchasing an additional 2,685,675 shares in the last quarter. Maple Rock Capital Partners Inc. acquired a new position in shares of Bausch Health Companies during the 3rd quarter worth approximately $16,850,000. Mackenzie Financial Corp raised its stake in shares of Bausch Health Companies by 111.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company's stock worth $16,612,000 after purchasing an additional 1,252,834 shares in the last quarter. Finally, Clearline Capital LP acquired a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $6,881,000. 78.65% of the stock is owned by institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.